Table 2.
Primary and Secondary Outcomesa
| Outcome | COVIG Group (n = 10) |
IVIG Group (n = 8) |
RR (95% CI) | Fisher’s Exact Test (P) |
|---|---|---|---|---|
| Severe course of COVID-19 | 2 (20) | 7 (88) | .23 (.06–.81) | .015 |
| Severe course of COVID-19 in seronegative patients | 1/8 (13) | 7/8 (88) | .14 (.02–.91) | .010 |
| Mortality at 28 days | 0 (0) | 3 (38) | … | |
| Median duration of hospitalizationb | 9 (4 to 15) | 9 (4 to 17) | … | |
| Indication for adjunctive ventilator support | 2 (20) | 5 (63) | … | |
| Admission to an intensive care unit due to respiratory insufficiency | 1 (10) | 3 (38) | … | |
| Lack of clinical improvement at day 7 or any day thereafter | 0 (0) | 3 (38) | … | |
| Readmission for COVID-19 | 0 (0) | 2 (25) | … |
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; COVIG, antisevere acute respiratory syndrome coronavirus 2 hyperimmune intravenous globulin; IVIG, intravenous immunoglobulin; RR, relative risk.
Data are n (%), median (interquartile range), or n/N (%).
Analyses exclude those who died during hospitalization.